多发性骨髓瘤的非典型临床表现综述
摘要
呈逐渐上升趋势，是血液系统中第 2 位的常见恶性肿瘤之一 2,3。目前，临床上对于 MM 的致病原因及具体发
病机制尚未完全阐述清楚，但分析以往临床病例资料可知其为骨髓内恶性浆细胞增殖或伴有侵润髓外，并分泌
大量单克隆免疫球蛋白对人体各器官组织造成一定的损害 4，因此其临床表现复杂多样。
关键词
全文:
PDF参考
[1]Medical Masterclass c, Firth J. Haematology:
multiple myeloma. Clin Med (Lond) 2019; 19(1): 58-60.
[2]Liu W, Liu J, Song Y, et al. Mortality of
lymphoma and myeloma in China, 2004-2017: an
observational study. J Hematol Oncol 2019; 12(1): 22.
[3]Wang S, Xu L, Feng J, et al. Prevalence and Incidence
of Multiple Myeloma in Urban Area in China: A National
Population-Based Analysis. Front Oncol 2019; 9: 1513.
[4]Riccomi G, Fornaciari G, Giuffra V. Multiple
myeloma in paleopathology: A critical review. Int J
Paleopathol 2019; 24: 201-12.
[5]Eslick R, Talaulikar D. Multiple myeloma: from
diagnosis to treatment. Aust Fam Physician 2013; 42(10):
684-8.
[6]Rajkumar SV, Kyle RA. Multiple myeloma:
diagnosis and treatment. Mayo Clin Proc 2005; 80(10):
1371-82.
[7]Kyle RA, Gertz MA, Witzig TE, et al. Review
of 1027 patients with newly diagnosed multiple myeloma.
Mayo Clin Proc 2003; 78(1): 21-33.
[8]Eleutherakis-Papaiakovou V, Bamias A, Gika
D, et al. Renal failure in multiple myeloma: incidence,
correlations, and prognostic significance. Leuk Lymphoma
2007; 48(2): 337-41.
[9]Palumbo A, Anderson K. Multiple myeloma. N
Engl J Med 2011; 364(11): 1046-60.
[10]Varettoni M, Corso A, Pica G, Mangiacavalli S,
Pascutto C, Lazzarino M. Incidence, presenting features and
outcome of extramedullary disease in multiple myeloma:
a longitudinal study on 1003 consecutive patients. Ann
Oncol 2010; 21(2): 325-30.
[11]Palumbo A, Bringhen S, Ludwig H, et al.
Personalized therapy in multiple myeloma according to patient
age and vulnerability: a report of the European Myeloma
Network (EMN). Blood 2011; 118(17): 4519-29.
[12]Plummer C, Driessen C, Szabo Z, Mateos MV.
Management of cardiovascular risk in patients with multiple
myeloma. Blood Cancer J 2019; 9(3): 26.
[13]Shah KB, Inoue Y, Mehra MR. Amyloidosis and
the heart: a comprehensive review. Arch Intern Med 2006;
166(17): 1805-13.
[14]Oberti L, Rognoni P, Barbiroli A, et al.
Concurrent structural and biophysical traits link with
immunoglobulin light chains amyloid propensity. Sci Rep
2017; 7(1): 16809.
[15]Falk RH, Alexander KM, Liao R, Dorbala S.
AL (Light-Chain) Cardiac Amyloidosis: A Review of
Diagnosis and Therapy. J Am Coll Cardiol 2016; 68(12):
1323-41.
[16]Thomas FB, Clausen KP, Greenberger NJ. Liver
disease in multiple myeloma. Arch Intern Med 1973;
132(2): 195-202.
[17]Pozzi C, Locatelli F. Kidney and liver
involvement in monoclonal light chain disorders. Semin
Nephrol 2002; 22(4): 319-30.
[18]Perez-Soler R, Esteban R, Allende E, Tornos
Salomo C, Julia A, Guardia J. Liver involvement in
multiple myeloma. Am J Hematol 1985; 20(1): 25-9.
[19]Chang SS, Lu CL, Tsay SH, Chang FY, Lee SD.
Amyloidosis-induced gastrointestinal bleeding in a patient with
multiple myeloma. J Clin Gastroenterol 2001; 32(2): 161-3.
[20]Lopes da Silva R. Extramedullary plasmacytoma
of the small intestine: clinical features, diagnosis and
treatment. J Dig Dis 2012; 13(1): 10-8.
[21]Lin M, Zhu J, Shen H, Huang J. Gastrointestinal
bleeding as an initial manifestation in asymptomatic
multiple myeloma: A case report and review of the
literature. Oncol Lett 2013; 5(1): 218-20.
[22]Daram SR, Paine ER, Swingley AF. Upper
gastrointestinal bleeding in a patient with multiple
myeloma. Gastroenterology 2012; 142(2): e8-9.
[23]DiMinno G, Coraggio F, Cerbone AM, et
al. A myeloma paraprotein with specificity for platelet
glycoprotein IIIa in a patient with a fatal bleeding disorder.
J Clin Invest 1986; 77(1): 157-64.
[24]Saif MW, Allegra CJ, Greenberg B. Bleeding
diathesis in multiple myeloma. J Hematother Stem Cell
Res 2001; 10(5): 657-60.
[25]Chakraborty SK, Chowdhury A, Kar S, Mondal
S, Basu S, Ahmed AA. Multiple myeloma presenting
as malabsorption syndrome due to amyloidosis. J Assoc
Physicians India 2000; 48(9): 931-2.
[26]Narvaez J, Hernandez MV, Ruiz JM, Vaquero
CG, Juanola X, Nollaa JM. Rituximab therapy for AAamyloidosis secondary to rheumatoid arthritis. Joint Bone
Spine 2011; 78(1): 101-3.
[27]Goranov S. Clinical problems of infectious
complications in patients with multiple myeloma. Folia
Med (Plovdiv) 1994; 36(1): 41-6.
[28]Hughes JC, Votaw ML. Pleural effusion in
multiple myeloma. Cancer 1979; 44(3): 1150-4.
[29]Kintzer JS, Jr., Rosenow EC, 3rd, Kyle RA.
Thoracic and pulmonary abnormalities in multiple
myeloma. A review of 958 cases. Arch Intern Med 1978;
138(5): 727-30.
[30]Kamble R, Wilson CS, Fassas A, et al. Malignant
pleural effusion of multiple myeloma: prognostic factors
and outcome. Leuk Lymphoma 2005; 46(8): 1137-42.
[31]Billecke L, Murga Penas EM, May AM, et al.
Cytogenetics of extramedullary manifestations in multiple
myeloma. Br J Haematol 2013; 161(1): 87-94.
[32]Rosinol L, Cibeira MT, Blade J, et al.
Extramedullary multiple myeloma escapes the effect of
thalidomide. Haematologica 2004; 89(7): 832-6.
(11 摘要 Views, 16 PDF Downloads)
Refbacks
- 当前没有refback。